Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp at RBC Capital Markets Global Healthcare Conference Transcript

May 16, 2023 / 02:30PM GMT
Release Date Price: $64.7 (-2.27%)
Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

RBC Capital Markets. We're really pleased to have our next presenting company Incyte here with us today. Representing Incyte, we have Christiana Stamoulis, their CFO, and Steven Stein, their Chief Medical Officer.

Christiana and Steven, thank you guys so much for being here.

Steven H. Stein
Incyte Corporation - Executive VP & Chief Medical Officer

Thank you.

Christiana Stamoulis
Incyte Corporation - Executive VP & CFO

Thank you.

Questions & Answers

Brian Corey Abrahams
RBC Capital Markets, Research Division - Senior Biotechnology Analyst

So there's a lot to talk about. A lot going on in the commercial and strategic and R&D front. And so we'll try to touch on as much as we can in the next 25 minutes. But maybe we can start with Opzelura, you're coming off of first quarter earnings. And where I would love to learn a little bit more about the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot